Retinal Pharmaceutical and Biologics Market to Grow to $13.9 Billion by 2022

October 16, 2017: By Market Scope

The retinal pharmaceuticals and biologics market is the biggest market segment in ophthalmology, and it keeps growing as the companies marketing Eylea (Regeneron, Bayer, and Santen) and Lucentis (Roche and Novartis) continue to acquire regulatory approvals for treating new disease indications with their products. Market Scope forecasts that the retinal pharmaceuticals market will grow at a compound annual growth rate (CAGR) of 6.2 percent a year, totaling $13.9 billion by 2022.

Market Scope estimates that nearly 355 million people around the globe suffer from some type of retinal disease or condition, and a small percentage suffer from more than one. We expect the number of people with retinal disease to exceed 404 million by 2022, with a compound annual rate of growth of 2.7 percent. Age-related macular degeneration (AMD) and diabetic eye diseases are the most common diseases of the retina, accounting for 89 percent of all cases of retinal disease.

Five major factors are shaping the market for retinal pharmaceuticals, including a growing number of people living past age 80, the evolving epidemic of diabetes, additional efforts to extend treatments to previously untreatable diseases, and efforts to reduce the burden of treatment through the development of longer-acting therapeutics.

More than 100 companies are aggressively seeking to find, develop, or produce pharmaceutical or biological treatments for noninfectious retinal disease, but only 27 have a notable product in the market or close to commercialization. Four of these companies combined earned more than 86 percent of total revenues in 2017: Novartis/Alcon, Roche/Genentech, Regeneron, and Bayer Health.

Market Scope published its 2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022 in October 2017. The report covers prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We look at the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and analyze treatment patterns and trends. We also forecast product demand in units and dollars, and we analyze market shares by product category. Our forecast also subdivides the retinal pharmaceuticals and biologics market into eight geographic/economic analytic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World.

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales